Navigation Links
Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Date:8/10/2009

ole

Binding of the non-structural protein NS4B to the 3' terminus of the HCV negative RNA strand is a recently identified target for drug intervention. The requirement of this target for viral replication has been genetically validated. The two component nature of this target, involving interaction between NS4B and HCV-RNA, creates mutational constraints that should decrease resistance to pharmacologic inhibitors, compared to agents designed against a single component target such as the NS3 protease. Clemizole hydrochloride was identified as a specific inhibitor of NS4B-RNA binding. Clemizole, a first generation antihistamine, was widely used in Europe and in the U.S. beginning in the late 1950's, marketed under various brand names, for the management of allergic disorders and various dermatological conditions. Clemizole is no longer marketed as a single agent antihistamine anywhere in the world.

"In the process of studying clemizole's newly discovered anti-HCV activity, we have found that it not only has several unique and remarkable features of its own that can make it ideal for hepatitis C, but clemizole also appears to be able to significantly increase the efficacy of other agents in clinical development," said Jeffrey Glenn, Founder of Eiger. "Together this suggests that clemizole has the potential to be an ideal component of all future anti-HCV cocktails."

About Eiger BioPharmaceuticals, Inc. www.eigerbio.com

Eiger is focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger investors include InterWest Partners

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
2. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
5. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
11. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- Today ... Dr. Christine Ginocchio discussed ... solution for rapid identification of microorganisms producing bloodstream ... and Chief of the Division of Infectious Disease ... 2nd largest not-for-profit, non-sectarian health system. ...
(Date:5/20/2013)... NEW YORK , May 20, 2013  Echo ... Rule 2.5 of the Irish Takeover Rules (the "Announcement"), ... Corporation, plc (NYSE: ELN ) to $12.50 ... financed, cash confirmed and not conditional on due diligence.  ... eliminated.  Royalty Pharma has reserved the right to waive ...
(Date:5/20/2013)...   Life Technologies Corporation (NASDAQ: ... Dx and 3500xL Dx Genetic Analyzers have been approved ... in Mexico for diagnostic use.  ... capabilities to serve the clinical end market in ... -based solutions.  The Applied Biosystems™ ...
Breaking Medicine Technology:Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3
(Date:5/20/2013)... 20 (HealthDay News) -- A child whose mother lived ... risk for developing a respiratory infection before the age ... at data involving nearly 1,300 pairs of mothers and ... participation while in their first trimester of pregnancy at ... percent of the mothers lived within 100 meters (about ...
(Date:5/20/2013)... the sweet flavor of orange juice into something so ... in colorful, animated detail check the latest ... Science video series at http://www.BytesizeScience.com , ... that the mainstay ingredients in toothpaste include a detergent ... you brush your teeth, SLS produces the foamy suds ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Join Seva Foundation ... concert at the Palace of Fine Arts Theater ... Uttal , C.C. White and Shimshai, with host Wavy Gravy. ... the world. , Reserved seats are $40 & ... with the artists and a front row seat at the ...
(Date:5/20/2013)... Cliff Lake Dental Care is pleased to announce that ... visiting the dentist office . The change was made to ... Here are the new office hours: Mondays- 8 a.m. to 1 ... to 1 p.m. and 2-5 p.m., Thursdays 7 a.m. to 12 ... open to take appointments only. Cliff Lake Dental wants to allow ...
(Date:5/20/2013)... May 20, 2013 T.E.N. announced ... this year’s prestigious Information Security Executive® Northeast Awards ... Awards include the Information Security Executive® of the ... executives who have made a positive impact on ... compliance, privacy and information security; and the ISE® ...
Breaking Medicine News(10 mins):Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Cliff Lake Dental Care Announces Office Hours Change 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3
... liver disease (NAFLD) is the most common cause of ... for patients with NAFLD is currently available//. Understanding the ... patients with NAFLD is important for patient counseling as ... ,To deal with these issues, researchers from Mayo Clinic ...
... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
... to start its Phase III cancer vaccine trial against ... is the new skin cancer vaccine developed by Antigenics.// ... 322 patients failed to meet the required statistically significance ... was not shown to have any better results compared ...
... news for adults with acne and resultant facial scarring. ... Surgery, the medical journal of the American Society for ... - or non-ablative - lasers showed significant improvement of ... common with ablative procedures, such as facial resurfacing, dermabrasion ...
... survival rate of women with breast cancer has increased by ... years//. The experts feel that the increase in breast cancer ... detection of breast cancer and also due to more effective ... of cancer. ,Professor Michel Coleman, Epidemiologist, Cancer Research ...
... found that it is better to insert drug-coated stents ... who have diabetes//. ,The study author Dr. ... University Hospital in Madrid said that the results of ... have poorer prognosis as compared to non-diabetics after angioplasty. ...
Cached Medicine News:Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2Health News:Breast cancer women has shown an increase in survival rates 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: